Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-12-31

AUTHORS

Amanda F Baker, Neale T Hanke, Barbara J Sands, Liliana Carbajal, Janet L Anderl, Linda L Garland

ABSTRACT

BACKGROUND: Carfilzomib (CFZ) is a proteasome inhibitor that selectively and irreversibly binds to its target and has been approved in the US for treatment of relapsed and refractory multiple myeloma. Phase 1B studies of CFZ reported signals of clinical activity in solid tumors, including small cell lung cancer (SCLC). The aim of this study was to investigate the activity of CFZ in lung cancer models. METHODS: A diverse panel of human lung cancer cell lines and a SHP77 small cell lung cancer xenograft model were used to investigate the anti-tumor activity of CFZ. RESULTS: CFZ treatment inhibited both the constitutive proteasome and the immunoproteasome in lung cancer cell lines. CFZ had marked anti-proliferative activity in A549, H1993, H520, H460, and H1299 non-small cell lung cancer (NSCLC) cell lines, with IC50 values after 96 hour exposure from <1.0 nM to 36 nM. CFZ had more variable effects in the SHP77 and DMS114 SCLC cell lines, with IC50 values at 96 hours from <1 nM to 203 nM. Western blot analysis of CFZ-treated H1993 and SHP77 cells showed cleavage of poly ADP ribose polymerase (PARP) and caspase-3, indicative of apoptosis, and induction of microtubule-associated protein-1 light chain-3B (LC3B), indicative of autophagy. In SHP77 flank xenograft tumors, CFZ monotherapy inhibited tumor growth and prolonged survival, while no additive or synergistic anti-tumor efficacy was observed for CFZ + cisplatin (CDDP). CONCLUSIONS: CFZ demonstrated anti-proliferative activity in lung cancer cell lines in vitro and resulted in a significant survival advantage in mice with SHP77 SCLC xenografts, supporting further pre-clinical and clinical investigations of CFZ in NSCLC and SCLC. More... »

PAGES

111

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s13046-014-0111-8

DOI

http://dx.doi.org/10.1186/s13046-014-0111-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1015832532

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25612802


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Apoptosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Proliferation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease Models, Animal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lung Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mice", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oligopeptides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proteasome Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Small Cell Lung Carcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Burden", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Xenograft Model Antitumor Assays", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Arizona Cancer Center, College of Medicine, Section of Hematology/Oncology, 1515 N Campbell Ave, Tucson, AZ USA", 
          "id": "http://www.grid.ac/institutes/grid.134563.6", 
          "name": [
            "University of Arizona Cancer Center, College of Medicine, Section of Hematology/Oncology, 1515 N Campbell Ave, Tucson, AZ USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Baker", 
        "givenName": "Amanda F", 
        "id": "sg:person.01067534552.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067534552.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Arizona Cancer Center, College of Medicine, Section of Hematology/Oncology, 1515 N Campbell Ave, Tucson, AZ USA", 
          "id": "http://www.grid.ac/institutes/grid.134563.6", 
          "name": [
            "University of Arizona Cancer Center, College of Medicine, Section of Hematology/Oncology, 1515 N Campbell Ave, Tucson, AZ USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hanke", 
        "givenName": "Neale T", 
        "id": "sg:person.01231024471.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231024471.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Arizona Cancer Center, College of Medicine, Section of Hematology/Oncology, 1515 N Campbell Ave, Tucson, AZ USA", 
          "id": "http://www.grid.ac/institutes/grid.134563.6", 
          "name": [
            "University of Arizona Cancer Center, College of Medicine, Section of Hematology/Oncology, 1515 N Campbell Ave, Tucson, AZ USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sands", 
        "givenName": "Barbara J", 
        "id": "sg:person.01151440600.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151440600.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Arizona Cancer Center, College of Medicine, Section of Hematology/Oncology, 1515 N Campbell Ave, Tucson, AZ USA", 
          "id": "http://www.grid.ac/institutes/grid.134563.6", 
          "name": [
            "University of Arizona Cancer Center, College of Medicine, Section of Hematology/Oncology, 1515 N Campbell Ave, Tucson, AZ USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carbajal", 
        "givenName": "Liliana", 
        "id": "sg:person.01274623716.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01274623716.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA USA", 
          "id": "http://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Anderl", 
        "givenName": "Janet L", 
        "id": "sg:person.01215615534.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215615534.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Arizona Cancer Center, College of Medicine, Section of Hematology/Oncology, 1515 N Campbell Ave, Tucson, AZ USA", 
          "id": "http://www.grid.ac/institutes/grid.134563.6", 
          "name": [
            "University of Arizona Cancer Center, College of Medicine, Section of Hematology/Oncology, 1515 N Campbell Ave, Tucson, AZ USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garland", 
        "givenName": "Linda L", 
        "id": "sg:person.01322145005.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322145005.35"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00280-013-2267-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034718690", 
          "https://doi.org/10.1007/s00280-013-2267-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002800051053", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022009924", 
          "https://doi.org/10.1007/s002800051053"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1207373", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012864607", 
          "https://doi.org/10.1038/sj.onc.1207373"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12032-008-9107-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008149084", 
          "https://doi.org/10.1007/s12032-008-9107-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13046-014-0077-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052399524", 
          "https://doi.org/10.1186/s13046-014-0077-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature07960", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043470791", 
          "https://doi.org/10.1038/nature07960"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1756-9966-29-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022407931", 
          "https://doi.org/10.1186/1756-9966-29-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/onc.2011.384", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008798576", 
          "https://doi.org/10.1038/onc.2011.384"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-12-31", 
    "datePublishedReg": "2014-12-31", 
    "description": "BACKGROUND: Carfilzomib (CFZ) is a proteasome inhibitor that selectively and irreversibly binds to its target and has been approved in the US for treatment of relapsed and refractory multiple myeloma. Phase 1B studies of CFZ reported signals of clinical activity in solid tumors, including small cell lung cancer (SCLC). The aim of this study was to investigate the activity of CFZ in lung cancer models.\nMETHODS: A diverse panel of human lung cancer cell lines and a SHP77 small cell lung cancer xenograft model were used to investigate the anti-tumor activity of CFZ.\nRESULTS: CFZ treatment inhibited both the constitutive proteasome and the immunoproteasome in lung cancer cell lines. CFZ had marked anti-proliferative activity in A549, H1993, H520, H460, and H1299 non-small cell lung cancer (NSCLC) cell lines, with IC50 values after 96 hour exposure from <1.0 nM to 36 nM. CFZ had more variable effects in the SHP77 and DMS114 SCLC cell lines, with IC50 values at 96 hours from <1 nM to 203 nM. Western blot analysis of CFZ-treated H1993 and SHP77 cells showed cleavage of poly ADP ribose polymerase (PARP) and caspase-3, indicative of apoptosis, and induction of microtubule-associated protein-1 light chain-3B (LC3B), indicative of autophagy. In SHP77 flank xenograft tumors, CFZ monotherapy inhibited tumor growth and prolonged survival, while no additive or synergistic anti-tumor efficacy was observed for CFZ + cisplatin (CDDP).\nCONCLUSIONS: CFZ demonstrated anti-proliferative activity in lung cancer cell lines in vitro and resulted in a significant survival advantage in mice with SHP77 SCLC xenografts, supporting further pre-clinical and clinical investigations of CFZ in NSCLC and SCLC.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s13046-014-0111-8", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1094159", 
        "issn": [
          "0392-9078", 
          "1756-9966"
        ], 
        "name": "Journal of Experimental & Clinical Cancer Research", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "33"
      }
    ], 
    "keywords": [
      "small cell lung cancer", 
      "lung cancer cell lines", 
      "cancer cell lines", 
      "lung cancer model", 
      "anti-tumor activity", 
      "poly ADP ribose polymerase", 
      "microtubule-associated protein-1 light chain-3B", 
      "small cell lung cancer model", 
      "cancer model", 
      "cell lung cancer xenograft model", 
      "cell lines", 
      "anti-proliferative activity", 
      "non-small cell lung cancer cell lines", 
      "non-small cell", 
      "cell lung cancer model", 
      "cell lung cancer cell lines", 
      "human lung cancer cell lines", 
      "lung cancer xenograft model", 
      "broad anti-tumor activity", 
      "phase 1b study", 
      "refractory multiple myeloma", 
      "cell lung cancer", 
      "significant survival advantage", 
      "anti-tumor efficacy", 
      "SCLC cell lines", 
      "cancer xenograft model", 
      "flank xenograft tumors", 
      "activity of carfilzomib", 
      "indicative of apoptosis", 
      "synergistic anti-tumor efficacy", 
      "CFZ treatment", 
      "SCLC xenografts", 
      "Western blot analysis", 
      "multiple myeloma", 
      "lung cancer", 
      "clinical activity", 
      "IC50 values", 
      "survival advantage", 
      "clinical investigation", 
      "xenograft tumors", 
      "xenograft model", 
      "ADP ribose polymerase", 
      "carfilzomib", 
      "solid tumors", 
      "tumor growth", 
      "proteasome inhibitors", 
      "constitutive proteasome", 
      "tumors", 
      "H1993", 
      "blot analysis", 
      "hours exposure", 
      "ribose polymerase", 
      "variable effects", 
      "treatment", 
      "SHP77 cells", 
      "monotherapy", 
      "NSCLC", 
      "myeloma", 
      "cells", 
      "activity", 
      "H520", 
      "xenografts", 
      "cancer", 
      "nM", 
      "mice", 
      "cisplatin", 
      "H460", 
      "diverse panel", 
      "efficacy", 
      "survival", 
      "immunoproteasome", 
      "caspase-3", 
      "study", 
      "inhibitors", 
      "apoptosis", 
      "A549", 
      "exposure", 
      "induction", 
      "hours", 
      "autophagy", 
      "aim", 
      "lines", 
      "target", 
      "indicative", 
      "proteasome", 
      "effect", 
      "panel", 
      "values", 
      "investigation", 
      "model", 
      "analysis", 
      "growth", 
      "polymerase", 
      "cleavage", 
      "uses", 
      "signals", 
      "advantages", 
      "SHP77 small cell lung cancer xenograft model", 
      "small cell lung cancer xenograft model", 
      "H1299 non-small cell lung cancer (NSCLC) cell lines", 
      "SHP77", 
      "DMS114 SCLC cell lines", 
      "protein-1 light chain-3B", 
      "light chain-3B", 
      "chain-3B", 
      "SHP77 flank xenograft tumors", 
      "CFZ monotherapy", 
      "SHP77 SCLC xenografts", 
      "pre-clinical non-small cell"
    ], 
    "name": "Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models", 
    "pagination": "111", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1015832532"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s13046-014-0111-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25612802"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s13046-014-0111-8", 
      "https://app.dimensions.ai/details/publication/pub.1015832532"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:34", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_632.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s13046-014-0111-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13046-014-0111-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13046-014-0111-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13046-014-0111-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13046-014-0111-8'


 

This table displays all metadata directly associated to this object as RDF triples.

309 TRIPLES      22 PREDICATES      160 URIs      144 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s13046-014-0111-8 schema:about N0132e486e9d045acaa5645ffaa43d40f
2 N02aaec8858424f2a8ecc264a35aaeb2f
3 N0ec56d70c7194860a39c94987835cae2
4 N1103e50fe6b8480ba1219bfaf8e3f2a7
5 N3eeacc62ddf94d04b6a8113cb8f6e4a0
6 N7385f430ad554337bf3ee613e6ac3a13
7 N9ae2b257e13348048c6e4cef756a21ab
8 Nb2bfe8a28cc44dad881e1856494c985e
9 Nbffcd95c83a34d9dbf2d2df97c8fd0d6
10 Nce81af53d38f4f78936a8ad2624d89a4
11 Nd04e5096cca84eff8dd81c62b3b104df
12 Nd6c29544373d419e989c31765ccb129c
13 Ne946e9b13ae3401b92dec21791441e62
14 Nf02d37161de741c2a6f3478fc9f79cd9
15 Nf2f02f66eb364a69bb2511fcb8f49934
16 Nf9dec7f08e8c4e8ba073983d99f05cb4
17 Nfb2988e922be42cb8bea96c24efbf13c
18 anzsrc-for:11
19 anzsrc-for:1112
20 schema:author N1a14472e3d364ddca979cb0a09cde900
21 schema:citation sg:pub.10.1007/s00280-013-2267-x
22 sg:pub.10.1007/s002800051053
23 sg:pub.10.1007/s12032-008-9107-6
24 sg:pub.10.1038/nature07960
25 sg:pub.10.1038/onc.2011.384
26 sg:pub.10.1038/sj.onc.1207373
27 sg:pub.10.1186/1756-9966-29-8
28 sg:pub.10.1186/s13046-014-0077-6
29 schema:datePublished 2014-12-31
30 schema:datePublishedReg 2014-12-31
31 schema:description BACKGROUND: Carfilzomib (CFZ) is a proteasome inhibitor that selectively and irreversibly binds to its target and has been approved in the US for treatment of relapsed and refractory multiple myeloma. Phase 1B studies of CFZ reported signals of clinical activity in solid tumors, including small cell lung cancer (SCLC). The aim of this study was to investigate the activity of CFZ in lung cancer models. METHODS: A diverse panel of human lung cancer cell lines and a SHP77 small cell lung cancer xenograft model were used to investigate the anti-tumor activity of CFZ. RESULTS: CFZ treatment inhibited both the constitutive proteasome and the immunoproteasome in lung cancer cell lines. CFZ had marked anti-proliferative activity in A549, H1993, H520, H460, and H1299 non-small cell lung cancer (NSCLC) cell lines, with IC50 values after 96 hour exposure from <1.0 nM to 36 nM. CFZ had more variable effects in the SHP77 and DMS114 SCLC cell lines, with IC50 values at 96 hours from <1 nM to 203 nM. Western blot analysis of CFZ-treated H1993 and SHP77 cells showed cleavage of poly ADP ribose polymerase (PARP) and caspase-3, indicative of apoptosis, and induction of microtubule-associated protein-1 light chain-3B (LC3B), indicative of autophagy. In SHP77 flank xenograft tumors, CFZ monotherapy inhibited tumor growth and prolonged survival, while no additive or synergistic anti-tumor efficacy was observed for CFZ + cisplatin (CDDP). CONCLUSIONS: CFZ demonstrated anti-proliferative activity in lung cancer cell lines in vitro and resulted in a significant survival advantage in mice with SHP77 SCLC xenografts, supporting further pre-clinical and clinical investigations of CFZ in NSCLC and SCLC.
32 schema:genre article
33 schema:inLanguage en
34 schema:isAccessibleForFree true
35 schema:isPartOf N2add827134744aca9d79cf1d20efb1c3
36 Nf76e3d9be97e4325aa4fdbda1b438581
37 sg:journal.1094159
38 schema:keywords A549
39 ADP ribose polymerase
40 CFZ monotherapy
41 CFZ treatment
42 DMS114 SCLC cell lines
43 H1299 non-small cell lung cancer (NSCLC) cell lines
44 H1993
45 H460
46 H520
47 IC50 values
48 NSCLC
49 SCLC cell lines
50 SCLC xenografts
51 SHP77
52 SHP77 SCLC xenografts
53 SHP77 cells
54 SHP77 flank xenograft tumors
55 SHP77 small cell lung cancer xenograft model
56 Western blot analysis
57 activity
58 activity of carfilzomib
59 advantages
60 aim
61 analysis
62 anti-proliferative activity
63 anti-tumor activity
64 anti-tumor efficacy
65 apoptosis
66 autophagy
67 blot analysis
68 broad anti-tumor activity
69 cancer
70 cancer cell lines
71 cancer model
72 cancer xenograft model
73 carfilzomib
74 caspase-3
75 cell lines
76 cell lung cancer
77 cell lung cancer cell lines
78 cell lung cancer model
79 cell lung cancer xenograft model
80 cells
81 chain-3B
82 cisplatin
83 cleavage
84 clinical activity
85 clinical investigation
86 constitutive proteasome
87 diverse panel
88 effect
89 efficacy
90 exposure
91 flank xenograft tumors
92 growth
93 hours
94 hours exposure
95 human lung cancer cell lines
96 immunoproteasome
97 indicative
98 indicative of apoptosis
99 induction
100 inhibitors
101 investigation
102 light chain-3B
103 lines
104 lung cancer
105 lung cancer cell lines
106 lung cancer model
107 lung cancer xenograft model
108 mice
109 microtubule-associated protein-1 light chain-3B
110 model
111 monotherapy
112 multiple myeloma
113 myeloma
114 nM
115 non-small cell
116 non-small cell lung cancer cell lines
117 panel
118 phase 1b study
119 poly ADP ribose polymerase
120 polymerase
121 pre-clinical non-small cell
122 proteasome
123 proteasome inhibitors
124 protein-1 light chain-3B
125 refractory multiple myeloma
126 ribose polymerase
127 signals
128 significant survival advantage
129 small cell lung cancer
130 small cell lung cancer model
131 small cell lung cancer xenograft model
132 solid tumors
133 study
134 survival
135 survival advantage
136 synergistic anti-tumor efficacy
137 target
138 treatment
139 tumor growth
140 tumors
141 uses
142 values
143 variable effects
144 xenograft model
145 xenograft tumors
146 xenografts
147 schema:name Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models
148 schema:pagination 111
149 schema:productId N50e8ad36c28c40d0892ed59b98cf0275
150 N51fa1a4e64634003ab6c695aeda93993
151 Ne709c7bbd4534e2bb45763b41facdc84
152 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015832532
153 https://doi.org/10.1186/s13046-014-0111-8
154 schema:sdDatePublished 2022-01-01T18:34
155 schema:sdLicense https://scigraph.springernature.com/explorer/license/
156 schema:sdPublisher Neb5013723ba04a73a25cd54689f74010
157 schema:url https://doi.org/10.1186/s13046-014-0111-8
158 sgo:license sg:explorer/license/
159 sgo:sdDataset articles
160 rdf:type schema:ScholarlyArticle
161 N0132e486e9d045acaa5645ffaa43d40f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Cell Proliferation
163 rdf:type schema:DefinedTerm
164 N02aaec8858424f2a8ecc264a35aaeb2f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Humans
166 rdf:type schema:DefinedTerm
167 N0ec56d70c7194860a39c94987835cae2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Cell Line, Tumor
169 rdf:type schema:DefinedTerm
170 N1103e50fe6b8480ba1219bfaf8e3f2a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Oligopeptides
172 rdf:type schema:DefinedTerm
173 N1a14472e3d364ddca979cb0a09cde900 rdf:first sg:person.01067534552.92
174 rdf:rest Nfe97be89a02d46ab8fa3426def6e7f77
175 N1ffdee976478450c837ea45bbf16e0fe rdf:first sg:person.01151440600.28
176 rdf:rest N888a7f827f3148be973a035636d84885
177 N2add827134744aca9d79cf1d20efb1c3 schema:volumeNumber 33
178 rdf:type schema:PublicationVolume
179 N3eeacc62ddf94d04b6a8113cb8f6e4a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Proteasome Inhibitors
181 rdf:type schema:DefinedTerm
182 N50e8ad36c28c40d0892ed59b98cf0275 schema:name dimensions_id
183 schema:value pub.1015832532
184 rdf:type schema:PropertyValue
185 N51fa1a4e64634003ab6c695aeda93993 schema:name pubmed_id
186 schema:value 25612802
187 rdf:type schema:PropertyValue
188 N7385f430ad554337bf3ee613e6ac3a13 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Lung Neoplasms
190 rdf:type schema:DefinedTerm
191 N888a7f827f3148be973a035636d84885 rdf:first sg:person.01274623716.39
192 rdf:rest Ndca08712870141cb9832fef2fc6cd32f
193 N9ae2b257e13348048c6e4cef756a21ab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Small Cell Lung Carcinoma
195 rdf:type schema:DefinedTerm
196 Nb2bfe8a28cc44dad881e1856494c985e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
197 schema:name Animals
198 rdf:type schema:DefinedTerm
199 Nbffcd95c83a34d9dbf2d2df97c8fd0d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Mice
201 rdf:type schema:DefinedTerm
202 Nce81af53d38f4f78936a8ad2624d89a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
203 schema:name Apoptosis
204 rdf:type schema:DefinedTerm
205 Nd04e5096cca84eff8dd81c62b3b104df schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
206 schema:name Female
207 rdf:type schema:DefinedTerm
208 Nd53afd4cf4194e18bab99e111d61bc20 rdf:first sg:person.01322145005.35
209 rdf:rest rdf:nil
210 Nd6c29544373d419e989c31765ccb129c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
211 schema:name Xenograft Model Antitumor Assays
212 rdf:type schema:DefinedTerm
213 Ndca08712870141cb9832fef2fc6cd32f rdf:first sg:person.01215615534.30
214 rdf:rest Nd53afd4cf4194e18bab99e111d61bc20
215 Ne709c7bbd4534e2bb45763b41facdc84 schema:name doi
216 schema:value 10.1186/s13046-014-0111-8
217 rdf:type schema:PropertyValue
218 Ne946e9b13ae3401b92dec21791441e62 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
219 schema:name Antineoplastic Agents
220 rdf:type schema:DefinedTerm
221 Neb5013723ba04a73a25cd54689f74010 schema:name Springer Nature - SN SciGraph project
222 rdf:type schema:Organization
223 Nf02d37161de741c2a6f3478fc9f79cd9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
224 schema:name Tumor Burden
225 rdf:type schema:DefinedTerm
226 Nf2f02f66eb364a69bb2511fcb8f49934 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
227 schema:name Cell Survival
228 rdf:type schema:DefinedTerm
229 Nf76e3d9be97e4325aa4fdbda1b438581 schema:issueNumber 1
230 rdf:type schema:PublicationIssue
231 Nf9dec7f08e8c4e8ba073983d99f05cb4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
232 schema:name Drug Resistance, Neoplasm
233 rdf:type schema:DefinedTerm
234 Nfb2988e922be42cb8bea96c24efbf13c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
235 schema:name Disease Models, Animal
236 rdf:type schema:DefinedTerm
237 Nfe97be89a02d46ab8fa3426def6e7f77 rdf:first sg:person.01231024471.66
238 rdf:rest N1ffdee976478450c837ea45bbf16e0fe
239 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
240 schema:name Medical and Health Sciences
241 rdf:type schema:DefinedTerm
242 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
243 schema:name Oncology and Carcinogenesis
244 rdf:type schema:DefinedTerm
245 sg:journal.1094159 schema:issn 0392-9078
246 1756-9966
247 schema:name Journal of Experimental & Clinical Cancer Research
248 schema:publisher Springer Nature
249 rdf:type schema:Periodical
250 sg:person.01067534552.92 schema:affiliation grid-institutes:grid.134563.6
251 schema:familyName Baker
252 schema:givenName Amanda F
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067534552.92
254 rdf:type schema:Person
255 sg:person.01151440600.28 schema:affiliation grid-institutes:grid.134563.6
256 schema:familyName Sands
257 schema:givenName Barbara J
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01151440600.28
259 rdf:type schema:Person
260 sg:person.01215615534.30 schema:affiliation grid-institutes:grid.417886.4
261 schema:familyName Anderl
262 schema:givenName Janet L
263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215615534.30
264 rdf:type schema:Person
265 sg:person.01231024471.66 schema:affiliation grid-institutes:grid.134563.6
266 schema:familyName Hanke
267 schema:givenName Neale T
268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231024471.66
269 rdf:type schema:Person
270 sg:person.01274623716.39 schema:affiliation grid-institutes:grid.134563.6
271 schema:familyName Carbajal
272 schema:givenName Liliana
273 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01274623716.39
274 rdf:type schema:Person
275 sg:person.01322145005.35 schema:affiliation grid-institutes:grid.134563.6
276 schema:familyName Garland
277 schema:givenName Linda L
278 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01322145005.35
279 rdf:type schema:Person
280 sg:pub.10.1007/s00280-013-2267-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1034718690
281 https://doi.org/10.1007/s00280-013-2267-x
282 rdf:type schema:CreativeWork
283 sg:pub.10.1007/s002800051053 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022009924
284 https://doi.org/10.1007/s002800051053
285 rdf:type schema:CreativeWork
286 sg:pub.10.1007/s12032-008-9107-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008149084
287 https://doi.org/10.1007/s12032-008-9107-6
288 rdf:type schema:CreativeWork
289 sg:pub.10.1038/nature07960 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043470791
290 https://doi.org/10.1038/nature07960
291 rdf:type schema:CreativeWork
292 sg:pub.10.1038/onc.2011.384 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008798576
293 https://doi.org/10.1038/onc.2011.384
294 rdf:type schema:CreativeWork
295 sg:pub.10.1038/sj.onc.1207373 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012864607
296 https://doi.org/10.1038/sj.onc.1207373
297 rdf:type schema:CreativeWork
298 sg:pub.10.1186/1756-9966-29-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022407931
299 https://doi.org/10.1186/1756-9966-29-8
300 rdf:type schema:CreativeWork
301 sg:pub.10.1186/s13046-014-0077-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052399524
302 https://doi.org/10.1186/s13046-014-0077-6
303 rdf:type schema:CreativeWork
304 grid-institutes:grid.134563.6 schema:alternateName University of Arizona Cancer Center, College of Medicine, Section of Hematology/Oncology, 1515 N Campbell Ave, Tucson, AZ USA
305 schema:name University of Arizona Cancer Center, College of Medicine, Section of Hematology/Oncology, 1515 N Campbell Ave, Tucson, AZ USA
306 rdf:type schema:Organization
307 grid-institutes:grid.417886.4 schema:alternateName Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA USA
308 schema:name Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA USA
309 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...